Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Paclitaxel
Synonyms
Therapy Description

Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Paclitaxel Taxol 7-Epipaclitaxel Antimicrotubule Agent 13 BCL2 Family Inhibitor 6 Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02312245 Phase II Topotecan Doxorubicin Paclitaxel Gemcitabine Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting USA 0
NCT02194829 Phase Ib/II Paclitaxel Gemcitabine Adavosertib Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01892046 Phase I Carboplatin SNX-5422 Paclitaxel Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Completed USA 0
NCT02957968 Phase II Decitabine + Pembrolizumab Cyclophosphamide + Doxorubicin Carboplatin + Paclitaxel Paclitaxel Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Recruiting USA 0
NCT02514551 Phase II Paclitaxel Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Completed USA | ITA | ESP | DEU | CAN | BEL 5
NCT04209855 Phase III Paclitaxel Pegylated liposomal-doxorubicin Mirvetuximab Soravtansine Topotecan A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 14
NCT02389751 Phase I Carboplatin Paclitaxel Ganetespib A Study of Ganetespib in Combination With Chemoradiation Completed USA 0
NCT01572038 Phase III Pertuzumab + Trastuzumab Nab-paclitaxel Docetaxel Paclitaxel A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE) Completed ITA | FRA | ESP | DEU | CAN | BEL | AUT 32
NCT01501487 FDA approved Cyclophosphamide + Docetaxel + Doxorubicin Cyclophosphamide + Epirubicin + Fluorouracil Paclitaxel Pegfilgrastim Cyclophosphamide + Docetaxel Cyclophosphamide + Doxorubicin Carboplatin + Docetaxel + Trastuzumab Docetaxel + Pertuzumab + Trastuzumab MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Completed USA 0
NCT03088059 Phase II Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil Biomarker-based Study in R/M SCCHN (UPSTREAM) Recruiting ITA | FRA | BEL 1
NCT03141359 Phase II Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC Recruiting USA 0
NCT03355157 FDA approved Exemestane + Palbociclib Tamoxifen Paclitaxel Exemestane Capecitabine Palbociclib + Tamoxifen Epirubicin Vinorelbine Fulvestrant + Palbociclib Fulvestrant Letrozole Letrozole + Palbociclib A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA) Recruiting DEU 0
NCT05255653 Phase II Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) Not yet recruiting FRA | CAN 2
NCT02819518 Phase III Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Active, not recruiting 0
NCT02073487 Phase II Paclitaxel Ado-trastuzumab emtansine + Lapatinib Lapatinib + Trastuzumab Nab-paclitaxel Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel Completed USA 0
NCT04109066 Phase III Paclitaxel Anthracycline + Cyclophosphamide + Nivolumab Nivolumab + Paclitaxel Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer (CheckMate 7FL) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 24
NCT04679064 Phase III Bevacizumab + Gemcitabine Dostarlimab-gxly + Niraparib Pegylated liposomal-doxorubicin Bevacizumab + Topotecan Paclitaxel Topotecan Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal-doxorubicin Gemcitabine Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33) Recruiting ITA 0
NCT02474173 Phase I Paclitaxel Onalespib Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer Active, not recruiting USA 0
NCT03517449 Phase III Lenvatinib + Pembrolizumab Paclitaxel Doxorubicin Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 15
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT02403895 Phase II Vistusertib Paclitaxel AZD2014 and Weekly Paclitaxel in Squamous NSCLC Terminated USA | ESP | DEU 0
NCT03125902 Phase III Paclitaxel Atezolizumab + Paclitaxel A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 18
NCT02134067 Phase I VIC-1911 Paclitaxel Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors Terminated USA 0
NCT00993655 Phase III Cisplatin Paclitaxel Carboplatin Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed USA | ESP | CAN 1
NCT02297230 Phase Ib/II Capecitabine Paclitaxel Paclitaxel + Trastuzumab Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics Terminated USA 0
NCT02322281 Phase III Pemetrexed Disodium Gemcitabine Paclitaxel Docetaxel Rociletinib TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy Terminated USA | ITA | FRA | ESP | DEU 5
NCT02502266 Phase II Topotecan Paclitaxel Doxorubicin Olaparib Cediranib Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA | CAN 3
NCT01248949 Phase I Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors Completed USA 0
NCT04879368 Phase III Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Recruiting USA | CAN 5
NCT04158362 Phase III Capecitabine Abemaciclib + Fulvestrant Abemaciclib + Letrozole Paclitaxel Abemaciclib + Anastrozole Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (AMBRE) Recruiting FRA 0
NCT02581943 Phase II Paclitaxel Pembrolizumab Carboplatin Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT01015222 Phase I Methylnaltrexone Bromide Dasatinib Paclitaxel Bevacizumab Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies Active, not recruiting USA 0
NCT02041533 Phase III Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 18
NCT02437812 Phase II Paclitaxel Carboplatin Metformin Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma Unknown status USA 0
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Completed USA | CAN 1
NCT01215136 Phase II Everolimus Paclitaxel First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Terminated USA 0
NCT04339738 Phase II Cabozantinib + Nivolumab Nivolumab + Paclitaxel Paclitaxel Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma Recruiting USA 1
NCT05092360 Phase III Pembrolizumab ALKS 4230 Topotecan Paclitaxel Pegylated liposomal-doxorubicin Gemcitabine ALKS 4230 + Pembrolizumab Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab (ARTISTRY-7) Recruiting USA 0
NCT01820754 Phase II Cisplatin Ipilimumab Carboplatin Paclitaxel Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT01653470 Phase I Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors Completed USA | CAN | BEL 0
NCT02470585 Phase III Carboplatin Paclitaxel Veliparib Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting USA | ESP 9
NCT02419417 Phase Ib/II BMS986158 Paclitaxel Study of BMS-986158 in Subjects With Select Advanced Solid Tumors Completed USA | FRA | ESP | CAN 1
NCT01407562 Phase I Carboplatin Paclitaxel Pazopanib Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT04374630 Phase II Afuresertib + Paclitaxel Paclitaxel Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II) Recruiting USA 0
NCT02367794 Phase III Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 18
NCT02483247 Phase Ib/II Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab Amcasertib A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer Completed USA | CAN 0
NCT03609047 Phase II Palbociclib Cyclophosphamide + Epirubicin Paclitaxel Cyclophosphamide + Docetaxel Cyclophosphamide + Doxorubicin Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches) Recruiting ITA | FRA | ESP | DEU | BEL 4
NCT04428151 Phase II Lenvatinib + Pembrolizumab Docetaxel Paclitaxel Capecitabine Cetuximab Lenvatinib Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) Recruiting USA | FRA | ESP | CAN 7
NCT04177108 Phase III Ipatasertib + Paclitaxel Atezolizumab + Paclitaxel Atezolizumab + Ipatasertib + Paclitaxel Paclitaxel A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL | AUT 30
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Completed USA | CAN 0
NCT04929041 Phase II Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Recruiting USA 0
NCT02122770 Phase I Paclitaxel Docetaxel Itraconazole Carboplatin MLN4924 Fluconazole Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors Completed USA 0
NCT01281150 Phase I Veliparib Paclitaxel Carboplatin Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 0
NCT02301988 Phase II Paclitaxel Ipatasertib A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer Completed USA | ESP 1
NCT03430843 Phase III Docetaxel Paclitaxel Tislelizumab Irinotecan A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL 5
NCT03770299 Phase II Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) Withdrawn 0
NCT02581982 Phase II Pembrolizumab Paclitaxel Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer Active, not recruiting USA 0
NCT04958785 Phase II Hu5F9-G4 + Nab-paclitaxel Hu5F9-G4 + Sacituzumab govitecan-hziy Nab-paclitaxel Paclitaxel Hu5F9-G4 + Paclitaxel Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast Cancer Recruiting USA 2
NCT05207709 Phase III Letrozole + Ribociclib Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Paclitaxel Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (HARMONIA) Recruiting ESP 1
NCT03769506 Phase III Methotrexate Cetuximab ASP-1929 Docetaxel Paclitaxel ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy Recruiting USA | ESP | BEL 3
NCT03783442 Phase III Cisplatin Paclitaxel Tislelizumab Oxaliplatin Fluorouracil Capecitabine A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL 10
NCT02576574 Phase III Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 35
NCT00989651 Phase I Bevacizumab + Veliparib Carboplatin Paclitaxel Cisplatin Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed USA 0
NCT05374512 Phase III Eribulin Nab-paclitaxel Paclitaxel Datopotamab Deruxtecan Carboplatin Capecitabine A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy Not yet recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 10
NCT01362374 Phase I Enzalutamide Paclitaxel Docetaxel Ipatasertib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors Completed USA | FRA | ESP 1
NCT01656538 Phase II Pelareorep Paclitaxel A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer Completed CAN 0
NCT01357161 Phase II Carboplatin Adavosertib Paclitaxel A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) Completed 0
NCT03639246 Phase Ib/II AVB-S6-500 + Paclitaxel AVB-S6-500 + Pegylated liposomal-doxorubicin Paclitaxel Pegylated liposomal-doxorubicin Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer Active, not recruiting USA 0
NCT02574078 Phase Ib/II Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) Completed USA 0
NCT04603183 Phase II Abemaciclib + Fulvestrant + Letrozole Paclitaxel ABemaciclib, ET +/- paclItaxel in aGgressive HR+/HER2- MBC trIaL (ABIGAIL) Recruiting ITA | ESP 1
NCT02412722 Phase I Sapanisertib Paclitaxel Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies Completed USA 0
NCT02625623 Phase III Avelumab Paclitaxel Irinotecan Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed USA | ITA | FRA | ESP | DEU | BEL 4
NCT01897441 Phase I Paclitaxel Paclitaxel + Trastuzumab Cyclophosphamide + Doxorubicin Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer Active, not recruiting USA 0
NCT02178956 Phase III Napabucasin Paclitaxel A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Completed USA | ITA | FRA | ESP | DEU | CAN | BEL 15
NCT03631199 Phase III Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 35
NCT04310007 Phase II Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer Recruiting USA 0
NCT02419495 Phase I Cyclophosphamide Pemetrexed Disodium Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin Selinexor in Combination With Standard Chemotherapy Recruiting USA 0
NCT01982448 Phase II Paclitaxel Cisplatin Cisplatin vs Paclitaxel for Triple Negative Breast Cancer Active, not recruiting USA 0
NCT02341456 Phase I Adavosertib Carboplatin Paclitaxel Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours Completed 3
NCT05238831 Phase II Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole SMMART Adaptive Clinical Treatment (ACT) Trial Not yet recruiting USA 0
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed USA 0
NCT04895358 Phase III Nab-paclitaxel Nab-paclitaxel + Pembrolizumab Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Capecitabine Daunoxome + Pembrolizumab Daunoxome Paclitaxel Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT 20
NCT02229149 Phase II Paclitaxel Docetaxel Pertuzumab + Trastuzumab Nab-paclitaxel Vinorelbine Trastuzumab Capecitabine Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer Active, not recruiting USA 0
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Completed USA 0
NCT02038647 Phase II Paclitaxel Alisertib Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) Completed USA | ITA | FRA | ESP | DEU | CAN | BEL 3
NCT02322814 Phase II Cobimetinib + Paclitaxel Paclitaxel Atezolizumab + Cobimetinib + Paclitaxel Atezolizumab + Cobimetinib + Nab-paclitaxel A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread Completed USA | ITA | FRA | ESP | BEL 8
NCT02551718 Phase I Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Completed USA 0
NCT01952249 Phase Ib/II Demcizumab Paclitaxel A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian Terminated USA 0
NCT03997123 Phase III Paclitaxel Capivasertib + Paclitaxel Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CapItello290) Recruiting USA | FRA | ESP | CAN 27
NCT02929576 Phase III Paclitaxel Enzalutamide + Paclitaxel Enzalutamide Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR) Withdrawn USA 0
NCT02551055 Phase I Docetaxel Paclitaxel Alisertib Mivavotinib Serabelisib MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma Terminated USA | ESP 0
NCT01320592 Phase I Palbociclib Paclitaxel PD0332991/Paclitaxel in Advanced Breast Cancer Completed USA 0
NCT01187199 Phase I Bevacizumab Paclitaxel Carboplatin Sorafenib Temsirolimus Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer Active, not recruiting USA 0
NCT02440425 Phase II Paclitaxel Pembrolizumab Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer Active, not recruiting USA 0
NCT02230319 Phase II Paclitaxel Prevention of Paclitaxel Neuropathy With Cryotherapy Unknown status USA 0
NCT02187991 Phase II Paclitaxel Alisertib + Paclitaxel Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Active, not recruiting USA 0
NCT04527991 Phase III Paclitaxel Docetaxel Vinflunine Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 15
NCT02390427 Phase I Trastuzumab Paclitaxel Pertuzumab Taselisib Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer Active, not recruiting USA 0
NCT00828009 Phase II Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT01641939 Phase III Docetaxel Paclitaxel Ado-trastuzumab emtansine A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL 21
NCT02162719 Phase II Ipatasertib + Paclitaxel Paclitaxel A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Completed USA | ITA | FRA | ESP | BEL 3
NCT01236547 Phase II Paclitaxel Pazopanib Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Active, not recruiting USA 0
NCT01249443 Phase I Carboplatin Vorinostat Paclitaxel Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Terminated USA 0
NCT04338399 Phase III Buparlisib + Paclitaxel Paclitaxel The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (BURAN) Recruiting USA 0
NCT01792050 Phase II Docetaxel Indoximod Paclitaxel Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Completed USA 1
NCT04989283 Phase II Carboplatin Atezolizumab + Cisplatin Atezolizumab + Paclitaxel Atezolizumab + Etoposide Cisplatin Etoposide Paclitaxel Atezolizumab + Carboplatin Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer Recruiting USA 0
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01493505 Phase III Carboplatin Paclitaxel Trebananib TRINOVA-3 Terminated USA | ITA | ESP | DEU | CAN | BEL | AUT 7
NCT01358877 Phase III Pertuzumab Epirubicin Cyclophosphamide Paclitaxel Docetaxel Trastuzumab Fluorouracil Carboplatin Doxorubicin A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 34
NCT03410693 Phase II Docetaxel Vinflunine Paclitaxel Rogaratinib Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1) Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 21
NCT01572727 Phase II Buparlisib + Paclitaxel Paclitaxel A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 14
NCT03337724 Phase II Ipatasertib + Paclitaxel Paclitaxel A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 23
NCT04494425 Phase III Capecitabine Nab-paclitaxel Trastuzumab deruxtecan Paclitaxel Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 20
NCT03398655 Phase III Paclitaxel Paclitaxel + VB-111 A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL) Active, not recruiting USA | ESP 3
NCT01779050 Phase II Trastuzumab Docetaxel Cyclophosphamide + Epirubicin Paclitaxel Cyclophosphamide + Epirubicin + Fluorouracil Carboplatin + Docetaxel Cyclophosphamide + Docetaxel Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Terminated USA 0
NCT02282020 Phase III Topotecan Paclitaxel Pegylated liposomal-doxorubicin Gemcitabine Olaparib Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3) Active, not recruiting USA | ITA | ESP | CAN | BEL 8
NCT04364048 Phase II Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Recruiting USA 0
NCT02725268 Phase II Paclitaxel Sapanisertib Sapanisertib + Serabelisib Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer Completed USA | ITA | ESP | DEU | CAN | BEL 4
NCT02620865 Phase Ib/II Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed USA 0
NCT02826161 Phase III Napabucasin + Paclitaxel Paclitaxel A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L) Terminated USA 0
NCT02364713 Phase II Pegylated liposomal-doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal-doxorubicin Gemcitabine MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting USA 0
NCT02117024 Phase II Cyclophosphamide + HS-110 Pemetrexed Disodium Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Terminated USA 0
NCT02264990 Phase III Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers Completed USA | ESP | DEU | CAN 16
NCT01796197 Phase II Cyclophosphamide + Doxorubicin Pertuzumab + Trastuzumab Paclitaxel Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa Active, not recruiting USA 0
NCT02855944 Phase III Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Active, not recruiting USA | ITA | ESP | CAN 8
NCT04729608 Phase III AVB-S6-500 + Paclitaxel Paclitaxel Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer Recruiting USA | ITA | FRA | ESP | CAN | BEL 3
NCT01962948 Phase II Paclitaxel Ganetespib Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Terminated USA 0
NCT04729387 Phase III Pegylated liposomal-doxorubicin Paclitaxel Alpelisib + Olaparib Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 17
NCT02366949 Phase I BAY1217389 + Paclitaxel Paclitaxel Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel Completed USA 1
NCT04215146 Phase II Paclitaxel Avelumab + Paclitaxel + Pelareorep Paclitaxel + Pelareorep A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Recruiting USA 0
NCT04711824 Phase Ib/II Nab-paclitaxel Cisplatin Durvalumab + Olaparib Paclitaxel Capecitabine Gemcitabine Carboplatin Eribulin Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases Recruiting USA 0
NCT02142738 Phase III Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed 0
NCT03734029 Phase III Trastuzumab deruxtecan Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 12
NCT02312804 Phase I Paclitaxel Carboplatin Infigratinib Ph Ib/BGJ398/Cervix and Other Solid Tumors Withdrawn 0
NCT04380636 Phase III Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Recruiting USA | ITA | FRA | ESP | DEU | CAN 18
NCT02651610 Phase II Bavituximab Paclitaxel Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer Withdrawn USA 0
NCT02302807 Phase III Paclitaxel Vinorelbine Atezolizumab Docetaxel A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 21
NCT01042522 Phase II Carboplatin Cisplatin Paclitaxel Etoposide Bleomycin Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Active, not recruiting USA 0


Additional content available in CKB BOOST